Participated · Series B · May 2020

Modulus Discovery is a preclinical-stage, computation-driven drug discovery company with offices in Tokyo and Boston that applies a proprietary simulation-driven platform to small-molecule discovery. The company runs a globally networked, fabless operational model and manages a discovery portfolio of more than 10 R&D programs. Since launching its discovery portfolio in 2018, Modulus reports positive in vivo proof-of-concept results for three of its most advanced lead programs. Its near-term plan is to advance those candidates toward first-in-human clinical trials in collaboration with partners. Modulus intends to use new capital to expand platform infrastructure, deepen industry and academic collaborations, and grow R&D and operations headcount. The firm focuses on therapeutic areas including oncology, chronic inflammation/immune disorders, and rare genetic conditions. Financially, Modulus has raised capital to date and is positioning to deliver multiple clinical candidates through partnerships and additional discovery collaborations. Modulus Discovery is a preclinical-stage, technology-driven drug discovery firm operating a computational discovery platform and networked operations with offices in Tokyo and Boston. The company focuses on discovering and optimizing small-molecule lead programs in oncology, chronic inflammation/immune disorders, and rare genetic conditions using supercomputing and computational biology. Modulus operates a virtual‑pharma model that does not own experimental lab space and instead leverages simulation and partnerships to advance candidates. The firm says it has identified and characterized several unique lead molecules and intends to bring them closer to clinical testing through partnerships with major industry players. Modulus plans to expand its portfolio of early programs and collaborations, including work with strategic partner PeptiDream, Inc. Financially, the company has raised a total of ¥3.51B (approximately $33.1M USD) to date across its Series A and B rounds. Modulus Discovery is a private, Tokyo-based preclinical drug discovery company that uses a proprietary computational platform and biology insights to design and generate small-molecule clinical candidates. The company operates a virtual pharma model and maintains an international team of drug design and disease biology experts with prior R&D experience at global pharma, biotech, and computational firms. Modulus plans to use new capital to further develop its platform, accelerate collaborative drug discovery programs with PeptiDream, and expand its R&D and business teams. Management also intends to initiate additional global collaborations with industry and academic partners that show strong synergy with Modulus’ capabilities. The company has offices and global virtual operations including Tokyo and Boston and reported progress from its collaboration with PeptiDream that produced several promising hit peptides. Financially, Modulus completed a Series A raise of ¥800M (approximately US$7.2M) to support these initiatives.